Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI - BioSpace

Chai Discovery announced a license agreement with Pfizer on an unspecified date. The agreement enables Pfizer to deploy Chai Discovery's AI platform, including the Chai-3 model, to accelerate drug discovery. The announcement was made via a press release.

The license grant gives Pfizer access to Chai's AI platform and the Chai-3 model, which is designed for molecular biology and drug design applications. Financial terms of the agreement were not disclosed. Chai Discovery specializes in using artificial intelligence for drug discovery.

The partnership reflects a broader trend of pharmaceutical companies collaborating with AI firms to streamline drug development. The goal is to leverage AI to reduce the time and cost of bringing new therapeutics to market. The deal is expected to support Pfizer's internal drug discovery efforts.